Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gijs van de Wetering

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 19, 2012
Time to incorporate time in cost-effectiveness analysisGijs van de Wetering, Willem H Woertman, Eddy M Adang
Pharmacoeconomics|January 19, 2013
A systematic and critical review of the evolving methods and applications of value of information in academia and practiceLotte Steuten, Gijs van de Wetering, Karin Groothuis-Oudshoorn, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 7, 2013
Cost-effectiveness on a local level: whether and when to adopt a new technologyWillem H Woertman, Gijs Van De Wetering, Eddy M M Adang
Health Economics|February 16, 2011
A model to correct for short-run inefficiencies in economic evaluations in healthcareGijs Van de Wetering, Willem H Woertman, Eddy M M Adang
Applied Health Economics and Health Policy|August 24, 2016
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level DataIstvan Majer, Gijs van de Wetering, Zoltan Polanyi, et al.
Journal of Medical Economics|June 5, 2025
A cost-effectiveness analysis of deucravacitinib <i>vs.</i> apremilast in moderate-to-severe psoriasis patients in JapanGijs van de Wetering, Hyunchung Kim, David Roberts, et al.
Journal of Medical Economics|March 17, 2022
Modification of treatment-sequence model with a customizable number of treatments to better reflect contemporary and future clinical practice in moderate to severe psoriasisGijs van de Wetering, Tim Ignacio, Devender Dhanda, et al.
International Journal of Technology Assessment in Health Care|March 31, 2015
Understanding and anticipating lag-time bias in cost-effectiveness studies: the role of time in cost-effectiveness analysisGijs van de Wetering, Marcel Olde Rikkert, Gert Jan van der Wilt, et al.
Journal of Medical Economics|December 17, 2025
Transforming PAH care in Italy: a clinical and economic evaluation of sotatercept add-on therapyMartina Paoletti, Andrea Marcellusi, Danilo Di Laura, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 30, 2012
Quantifying short run cost-effectiveness during a gradual implementation processGijs van de Wetering, Willem H Woertman, Andre L Verbeek, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 19, 2012
Time to incorporate time in cost-effectiveness analysisGijs van de Wetering, Willem H Woertman, Eddy M Adang
Pharmacoeconomics|January 19, 2013
A systematic and critical review of the evolving methods and applications of value of information in academia and practiceLotte Steuten, Gijs van de Wetering, Karin Groothuis-Oudshoorn, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 7, 2013
Cost-effectiveness on a local level: whether and when to adopt a new technologyWillem H Woertman, Gijs Van De Wetering, Eddy M M Adang
Health Economics|February 16, 2011
A model to correct for short-run inefficiencies in economic evaluations in healthcareGijs Van de Wetering, Willem H Woertman, Eddy M M Adang
Applied Health Economics and Health Policy|August 24, 2016
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level DataIstvan Majer, Gijs van de Wetering, Zoltan Polanyi, et al.
Journal of Medical Economics|June 5, 2025
A cost-effectiveness analysis of deucravacitinib <i>vs.</i> apremilast in moderate-to-severe psoriasis patients in JapanGijs van de Wetering, Hyunchung Kim, David Roberts, et al.
Journal of Medical Economics|March 17, 2022
Modification of treatment-sequence model with a customizable number of treatments to better reflect contemporary and future clinical practice in moderate to severe psoriasisGijs van de Wetering, Tim Ignacio, Devender Dhanda, et al.
International Journal of Technology Assessment in Health Care|March 31, 2015
Understanding and anticipating lag-time bias in cost-effectiveness studies: the role of time in cost-effectiveness analysisGijs van de Wetering, Marcel Olde Rikkert, Gert Jan van der Wilt, et al.
Journal of Medical Economics|December 17, 2025
Transforming PAH care in Italy: a clinical and economic evaluation of sotatercept add-on therapyMartina Paoletti, Andrea Marcellusi, Danilo Di Laura, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 30, 2012
Quantifying short run cost-effectiveness during a gradual implementation processGijs van de Wetering, Willem H Woertman, Andre L Verbeek, et al.
Pageof 2